Abstracts tagged "pain"

Abstract Number: 1499 • ACR Convergence 2022
The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control in Patients with Axial Spondyloarthritis: A Study from the CorEvitas PsA/SpA Registry
Philip J Mease¹, Robert McLean², Taylor Blachley², Nicole Middaugh², Manish Mittal³, Jerry Clewell³, Heather Jones⁴ and Alexis Ogdie⁵, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³AbbVie, Inc., North Chicago, IL, ⁴AbbVie, Inc., Chicago, IL, ⁵Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Axial spondyloarthritis (AxSpA) is a chronic inflammatory disease characterized by inflammatory back pain, morning stiffness, and reduced functional capacity. Approved therapies for AxSpA include…
Abstract Number: 1891 • ACR Convergence 2022
Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab: A Randomized Placebo-Controlled Trial
Walter P Maksymowych¹, Louis Bessette², Robert G Lambert³, Amanda Carapellucci⁴ and Tom Appleton⁵, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴CARE Arthritis LTD, Edmonton, AB, Canada, ⁵The University of Western Ontario, London, ON, Canada
Background/Purpose: Recent RCTs demonstrated that TNFα inhibition has no effect on pain and MRI-detected synovitis or bone marrow lesions in patients with erosive hand OA.…
Abstract Number: 1992 • ACR Convergence 2022
Burden of Pain for Patients in the CorEvitasTM Rheumatoid Arthritis Registry
Joshua Baker¹, J Morel Symons², Jud C Janak³, Page Moore³, Elizabeth Kohl³, Bernice Gershenson³, Oksana Pugach³, Dave Webb⁴, Alan A Martin⁴, Didier Saurigny⁵ and Marguerite Bracher⁵, ¹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ²GlaxoSmithKline, Collegeville, PA, ³CorEvitas, LLC, Waltham, MA, ⁴GlaxoSmithKline, Brentford, United Kingdom, ⁵GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Pain is a hallmark symptom of RA that impacts patients' quality of life and informs therapeutic decisions that aim to reduce joint inflammation and…
Abstract Number: 0402 • ACR Convergence 2022
Opioid Use and Healthcare Utilization in Adults with PsA and AS
Alexis Ogdie¹, Sofia Pedro², Jean Liew³ and Kaleb Michaud⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Boston University, Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Opioid use among individuals with spondyloarthritis is common, reported to be ~20-30% in some cohorts. Data on whether this subset of patients have higher…
Abstract Number: 0925 • ACR Convergence 2022
Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis
Mengdong He¹, Yvonne Lee², Yinzhu Jin³, Rishi Desai³, Seanna Vine³ and Seoyoung Kim³, ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Northwestern University, Chicago, IL, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Chronic pain associated with rheumatoid arthritis (RA) leads to impaired patient function and quality of life. Prior studies suggest initiation of disease-modifying antirheumatic drugs…
Abstract Number: 1590 • ACR Convergence 2022
Pain and Treatment Switching Among Patients in the CorEvitasTM Rheumatoid Arthritis Registry
Joshua Baker¹, J Morel Symons², Jud C Janak³, Oksana Pugach³, Elizabeth Kohl³, Miao Yu³, Dave Webb⁴, Alan A Martin⁴, Didier Saurigny⁵ and Marguerite Bracher⁵, ¹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ²GlaxoSmithKline, Collegeville, PA, ³CorEvitas, LLC, Waltham, MA, ⁴GlaxoSmithKline, Brentford, United Kingdom, ⁵GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: For many patients with RA on targeted therapies, the chronic burden of pain leads to therapies being deemed suboptimally effective and may affect treatment…
Abstract Number: 1892 • ACR Convergence 2022
Genicular Nerve Block for Pain Management in Patients with Knee Osteoarthritis: A Randomised Double-blind Placebo Controlled Trial
Ernst Shanahan¹, Fin Cai², Frank Voyvodic², Suellen Lyne², Richard Woodman¹, Kokum Dissanayake², Kate Paddick², Giovanna Cheung² and Lucinda Robinson², ¹Flinders University, Adelaide, Australia, ²SALHN, Adelaide, Australia
Background/Purpose: To determine whether Genicular Nerve Block (GNB) is an efficacious treatment for patients with knee osteoarthritis (OA)Methods: Adults with symptomatic knee OA for greater than 3…
Abstract Number: 2118 • ACR Convergence 2022
Achieving Increasingly Stringent Clinical Disease Control Criteria Is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Jessica Walsh¹, Laura Coates², Philip J Mease³, Joseph Merola⁴, Peter Nash⁵, Alexis Ogdie⁶, William Tillett⁷, Paolo Gisondi⁸, Barbara Ink⁹, Deepak Assudani⁹, Rajan Bajracharya⁹, Jérémy Lambert¹⁰, Vanessa Taieb¹¹, Damon Willems¹² and Lars Erik¹³, ¹University of Utah, Salt Lake City, UT, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵School of Medicine, Griffith University, Sunshine Coast, Australia, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, Verona, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Colombes, France, Irigny, France, ¹¹UCB Pharma, Colombes, France, ¹²UCB Pharma, Brussels, Belgium, ¹³Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark
Background/Purpose: Examine the association between achieving increasingly stringent clinical disease control criteria and patient-centric measures of physical function and pain in patients with PsA, using…
Abstract Number: 0428 • ACR Convergence 2022
Difficult to Treat Spondyloarthritis: Patients with a High Biologic Switch Rate and the Factors Influencing It; A Real World as Clinic Experience
Devika dua and Tim Blake, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom
Background/Purpose: To determine if there is a significant variation in biologic usage in axSpa patients and to identify factors associated with it.Methods: We collected retrospective…
Abstract Number: 1128 • ACR Convergence 2022
The Causal Association Between Osteoarthritis and Common Comorbidities: A Mendelian Randomisation Study
William Thompson¹, Subhashisa Swain², Sizheng Zhao³, Anne Kamps⁴, Carol Coupland⁵, Chang-Fu Kuo⁶, Michael Doherty⁵ and Weiya Zhang⁵, ¹University of Nottingham, Exeter, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³The University of Manchester, Manchester, United Kingdom, ⁴Erasmus University Medical Centre, Rotterdam, Netherlands, ⁵University of Nottingham, Nottingham, United Kingdom, ⁶Chang Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: Osteoarthritis (OA) is the most common cause of joint pain and a major cause of disability. OA commonly associates with other conditions, such as…
Abstract Number: 1614 • ACR Convergence 2022
Females with Non-Radiographic but Not with Radiographic Axial Spondyloarthritis Are Less Likely to Achieve Inactive Disease State Than Males: Results from a Multicountry Prospective Observational Study
Denis Poddubnyy¹, Joachim Sieper², Servet Akar³, Santiago Muñoz-Fernández⁴, Hildrun Haibel², Torsten Diekhoff⁵, Mikhail Protopopov⁶, Elisabeth Altmaier⁷, Fabiana Ganz⁸ and Robert Inman⁹, ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Charité - Universitätsmedizin, Berlin, Berlin, Germany, ³Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁴Servicio de Reumatología, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain, ⁵Department of Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany, ⁷GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, ⁸AbbVie, Inc., Luzern, Switzerland, ⁹University Health Network, Toronto, ON, Canada
Background/Purpose: Emerging evidence suggests that men and women experience axial spondyloarthritis (axSpA) differently. Some studies suggested that the probability of treatment response was lower in…
Abstract Number: 1893 • ACR Convergence 2022
Antihistamine Use and Structural Progression of Knee OA: A Post-Hoc Analysis of Two Phase 3 Clinical Trials
Asger Bihlet¹, Claire Miller¹, Inger Byrjalsen¹, Morten Karsdal², Jeppe Andersen¹, Tharaknath Rao³ and Matthew Baker⁴, ¹NBCD, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Mobility Bio, San Diego, CA, ⁴Mobility Bio, San Diego
Background/Purpose: Prior studies indicate that mast cells are involved in chronic inflammation and that their activity in the synovium may contribute to structural progression of…
Abstract Number: 2119 • ACR Convergence 2022
Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
M. Elaine Husni¹, Philip J Mease², Joseph Merola³, Frank Behrens⁴, Ennio Giulio Favalli⁵, Dennis McGonagle⁶, William Tillett⁷, Shigeyoshi Tsuji⁸, Barbara Ink⁹, Deepak Assudani⁹, Rajan Bajracharya⁹, Jason Coarse¹⁰, Jérémy Lambert¹¹ and Laure Gossec¹², ¹Cleveland Clinic, Cleveland, OH, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ³Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁵University of Milan, ASST Gaetano Pini-CTO Institute, Milano, Italy, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹¹UCB Pharma, Colombes, France, Irigny, France, ¹²Sorbonne Université, Paris, France
Background/Purpose: Patients with psoriatic arthritis (PsA) have identified fatigue and pain as important features relevant to their burden of disease.1 Bimekizumab (BKZ), a monoclonal IgG1…
Abstract Number: 0505 • ACR Convergence 2022
Longitudinal Trajectories of Central Pain Sensitization in People with or at Risk of Knee Osteoarthritis
Kosaku Aoyagi¹, Na Wang², Laura Frey-Law³, Cora E. Lewis⁴, Michael Nevitt⁵ and Tuhina Neogi², ¹Boston University, Quincy, MA, ²Boston University School of Medicine, Boston, MA, ³University of Iowa, Iowa City, IA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of California at San Francisco, Orinda, CA
Background/Purpose: Central pain sensitization is a major contributor to pain severity in knee osteoarthritis (OA). Central sensitization is induced by neuroplastic changes in the central…
Abstract Number: 1213 • ACR Convergence 2022
Trends of Opioid Prescriptions and Impact of the COVID-19 Pandemic Among Patients with Musculoskeletal Diseases Between 2006-2021
Joyce (Yun-Ting) Huang¹, David Jenkins², Belay Birlie Yimer¹, Jose Benitez-Aurioles², Niels Peek², Mark Lunt¹, Will Dixon³ and Meghna Jani¹, ¹Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, United Kingdom, ²Division of Informatics, The University of Manchester, Manchester, United Kingdom, ³The University of Manchester, Manchester, United Kingdom
Background/Purpose: Opioid prescribing has contributed to a North American epidemic with increasing trends in several European countries. Rheumatic and musculoskeletal diseases (RMDs) are one of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].